|
| related topics |
| {operation, international, foreign} |
| {product, liability, claim} |
| {regulation, government, change} |
| {product, market, service} |
| {operation, natural, condition} |
| {acquisition, growth, future} |
|
|
Our inability to successfully expand the business, through internal research and development, marketing partnerships and acquisitions, could have a material adverse effect on our business
If we are unable to successfully keep pace with technological advances in the medical field and the standards for transfusion medicine, our business, financial condition and results of operation could be adversely affected.
As a medical device manufacturer we are subject to a number of existing laws and regulations, non-compliance with those laws or regulations could adversely affect our financial condition and results of operations.
the manufacture of health care products could also require us to identify alternate material(s), which may be at higher costs. The number of eligible blood donors is influenced by government regulations (including travel restrictions, health history, etc.) and other economic and sociological factors. Changes in donation related regulations could have significant immediate effects on the population of eligible donors.
We are subject to various actions by government authorities that regulate medical devices including: product recalls, orders to cease manufacturing or distribution activities, and other sanctions or penalties.
Many of our competitors have significantly greater financial and other resources. Their greater financial resources may allow them to more rapidly develop new technologies, and more quickly address changes in customer requirements.
As a multinational corporation, we are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.
We are subject to the risks of international economic and political conditions.
We are subject to the risks associated with communicable diseases. A significant outbreak of a disease could reduce the demand for our products and affect our ability to provide our customers with products and services.
We sell our products in certain emerging economies.
In many of the international markets in which we do business, including certain parts of Europe, Russia and Asia, our employees, agents or distributors offer to sell our products
Full 10-K form ▸
|
|
| related documents |
| 874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE |
| 313143--5/27/2008--HAEMONETICS_CORP |
| 874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE |
| 10795--11/26/2008--BECTON_DICKINSON_&_CO |
| 1037115--3/31/2010--ORBIT_FR_INC |
| 14693--6/28/2007--BROWN_FORMAN_CORP |
| 72331--12/21/2007--NORDSON_CORP |
| 882835--2/29/2008--ROPER_INDUSTRIES_INC_/DE/ |
| 104169--3/29/2006--WAL_MART_STORES_INC |
| 12355--2/15/2006--BLACK_&_DECKER_CORP |
| 932696--2/25/2010--INSIGHT_ENTERPRISES_INC |
| 10795--11/30/2006--BECTON_DICKINSON_&_CO |
| 10795--11/23/2007--BECTON_DICKINSON_&_CO |
| 10081--2/29/2008--BARR_PHARMACEUTICALS_INC |
| 746598--9/28/2007--BRADY_CORP |
| 708850--8/28/2009--DIONEX_CORP_/DE |
| 911160--6/2/2010--RF_MICRO_DEVICES_INC |
| 10456--2/19/2009--BAXTER_INTERNATIONAL_INC |
| 929987--2/22/2006--GUIDANT_CORP |
| 1110783--10/26/2007--MONSANTO_CO_/NEW/ |
| 10795--11/24/2010--BECTON_DICKINSON_&_CO |
| 742112--3/1/2007--INVACARE_CORP |
| 275053--3/16/2010--NATURES_SUNSHINE_PRODUCTS_INC |
| 20--3/13/2009--K_TRON_INTERNATIONAL_INC |
| 1037115--3/31/2008--ORBIT_FR_INC |
| 1037115--4/2/2007--ORBIT_FR_INC |
| 14693--6/29/2006--BROWN_FORMAN_CORP |
| 1002037--12/8/2008--LEARNING_TREE_INTERNATIONAL_INC |
| 1006045--4/10/2008--IRIDEX_CORP |
| 1158420--1/16/2007--CHINA_AGRO_SCIENCES_CORP. |
|